Leptomeningeal metastases (LM) from solid tumours, lymphoma and leukaemia are characterized by multifocal neurological deficits with a high mortality rate. Early diagnosis and initiation of treatment are essential to kerb neurological deterioration. However, this is not always possible as 25% of cerebrospinal fluid samples produce false-negative results at first cytological examination. The identification of biomarkers that allow stratification of individuals according to risk for developing LM would be a major benefit. Proteomic-based approaches are now in increasing use for this purpose, and these are reviewed in this chapter with a focus on cerebrospinal fluid (CSF) analyses. The construction of a CSF proteome disease database would also facilitate analysis of other neurological disorders.
CITATION STYLE
Galicia, N., Díez, P., Dégano, R. M., Guest, P. C., Ibarrola, N., & Fuentes, M. (2017). Proteomic biomarker identification in cerebrospinal fluid for leptomeningeal metastases with neurological complications. In Advances in Experimental Medicine and Biology (Vol. 974, pp. 85–96). Springer New York LLC. https://doi.org/10.1007/978-3-319-52479-5_5
Mendeley helps you to discover research relevant for your work.